Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
4.120
-0.050 (-1.20%)
At close: Nov 22, 2024, 4:00 PM
4.320
+0.200 (4.85%)
After-hours: Nov 22, 2024, 4:20 PM EST
Company Description
Skye Bioscience, Inc., a biopharmaceutical company, focuses on unlocking new therapeutic pathways for metabolic health through the development of molecules that modulate G-protein coupled receptors.
The company is conducting a Phase 2 clinical trial in obesity for nimacimab, a negative allosteric modulating antibody that peripherally inhibits CB1.
This study is also assessing the combination of nimacimab and a GLP-1R agonist (Wegovy). The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021.
The company is headquartered in San Diego, California.
Skye Bioscience, Inc.
| Country | United States |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 11 |
| CEO | Punit Dhillon |
Contact Details
Address: 11250 El Camino Real, Suite 100 San Diego, California 92130 United States | |
| Phone | 858 410 0266 |
| Website | skyebioscience.com |
Stock Details
| Ticker Symbol | SKYE |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001516551 |
| CUSIP Number | 83086J101 |
| ISIN Number | US83086J2006 |
| Employer ID | 45-0692882 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Punit S. Dhillon B.A. | President, Chief Executive Officer, Secretary and Director |
| Kaitlyn Melanie Arsenault CPA | Chief Financial Officer |
| Dr. Christopher G. Twitty Ph.D. | Chief Scientific Officer |
| Tu Diep M.Sc. | Chief Development Officer |
| Dr. Puneet S. Arora FACE, M.D., M.S. | Chief Medical Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 15, 2024 | 144 | Filing |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 7, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Nov 7, 2024 | 10-Q | Quarterly Report |
| Nov 7, 2024 | 8-K | Current Report |
| Oct 29, 2024 | 8-K | Current Report |